Literature DB >> 12109063

Vector delivery methods and targeting strategies for gene therapy of brain tumors.

N G Rainov1, C M Kramm.   

Abstract

Efficient virus and non-virus vector systems for gene transfer to tumor cells have been developed and tested in cell culture and in animal experiments. With some of the earliest and most comprehensively evaluated vectors, such as retroviruses, advanced clinical trials were performed in tumor patients. Malignant primary brain tumors (gliomas) have been chosen for the first clinical studies on novel gene therapy approaches because these tumors are non-metastatic and develop on the largely postmitotic background of normal glial and neuronal tissue. However, the human cancer gene therapy studies performed so far were not as successful as preclinical animal experiments. Furthermore, the clinical studies did not address major limiting factors for in vivo gene therapy, such as insufficient gene transfer rates to the tumor with the used local delivery modalities, and the resulting inability of a particular transgene-prodrug system to confer permanently eradicating cytotoxicity to the whole neoplasm. Critical evaluation of gene transfer and therapy studies has led to the conclusion that, even using identical vectors, the anatomical route of vector administration can dramatically affect both the efficiency of tumor transduction and its spatial distribution, as well as the extent of intratumoral and intracerebral transgene expression. This review concentrates on different physical methods for vector delivery to malignant primary brain tumors in experimental or clinical settings: stereotactic or direct intratumoral injection or convection-enhanced bulk-flow interstitial delivery; intrathecal and intraventricular injection; and intravascular infusion with or without modification of the blood-tumor-barrier. The advantages and drawbacks of the different modes and delivery routes of in vivo vector application, and the possibilities for tumor targeting by modifications of the native tropism of virus vectors or by using tissue-specific or inducible transgene expression are summarized.

Entities:  

Mesh:

Year:  2001        PMID: 12109063     DOI: 10.2174/1566523013348445

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  9 in total

Review 1.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

2.  Clinical development of experimental therapies for malignant glioma.

Authors:  Nikolai G Rainov; Volkmar Heidecke
Journal:  Sultan Qaboos Univ Med J       Date:  2011-02-12

3.  Advances in Systemic siRNA Delivery.

Authors:  Qixin Leng; Martin C Woodle; Patrick Y Lu; A James Mixson
Journal:  Drugs Future       Date:  2009-09       Impact factor: 0.148

Review 4.  Clinical trials with retrovirus mediated gene therapy--what have we learned?

Authors:  Nikolai G Rainov; Huan Ren
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

5.  Migration of human neural stem cells toward an intracranial glioma.

Authors:  Jeong Yong Jeon; Jeung Hee An; Seung Up Kim; Hye Gyeong Park; Myung Ae Lee
Journal:  Exp Mol Med       Date:  2008-02-29       Impact factor: 8.718

6.  A novel newborn rat kernicterus model created by injecting a bilirubin solution into the cisterna magna.

Authors:  Sijie Song; Ying Hu; Xianfang Gu; Feifei Si; Ziyu Hua
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

7.  A New Method for the Visualization of Living Dopaminergic Neurons and Prospects for Using It to Develop Targeted Drug Delivery to These Cells.

Authors:  Victor Blokhin; Alina V Lavrova; Sergey A Surkov; Eduard R Mingazov; Natalia M Gretskaya; Vladimir V Bezuglov; Michael V Ugrumov
Journal:  Int J Mol Sci       Date:  2022-03-27       Impact factor: 5.923

8.  Prodrug converting enzyme gene delivery by L. monocytogenes.

Authors:  Jochen Stritzker; Sabine Pilgrim; Aladar A Szalay; Werner Goebel
Journal:  BMC Cancer       Date:  2008-04-10       Impact factor: 4.430

Review 9.  Drug releasing systems in cardiovascular tissue engineering.

Authors:  Cristiano Spadaccio; Massimo Chello; Marcella Trombetta; Alberto Rainer; Yoshiya Toyoda; Jorge A Genovese
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.